Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Garmo

Showing results (111-120 of 261) with videos related to

Pageof 27
Sort By:
International Journal of Cancer|June 2, 2011
The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS studyMieke Van Hemelrijck, Hans Garmo, Niklas Hammar, et al.
Cancer|April 28, 2011
Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucoseMieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al.
Journal of the National Cancer Institute|August 21, 2010
Effects of prostate-specific antigen testing on familial prostate cancer risk estimatesOla Bratt, Hans Garmo, Jan Adolfsson, et al.
Scandinavian Journal of Urology|April 28, 2020
Adherence to guidelines for androgen deprivation therapy after radical prostatectomy: Swedish population-based studyMagdalena Lycken, Linda Drevin, Hans Garmo, et al.
Plos One|July 23, 2014
Incidence of second malignancies for prostate cancerMieke Van Hemelrijck, Anita Feller, Hans Garmo, et al.
The Journal of Urology|May 13, 2014
Nationwide population based study of infections after transrectal ultrasound guided prostate biopsyKarl-Johan Lundström, Linda Drevin, Stefan Carlsson, et al.
Acta Oncologica (Stockholm, Sweden)|October 31, 2018
Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational studyFrederik Birkebæk Thomsen, Cecilia Bosco, Hans Garmo, et al.
Scandinavian Journal of Urology|November 13, 2023
Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in SwedenRolf Gedeborg, Fredrik Sandin, Camilla Thellenberg-Karlsson, et al.
The Journal of Sexual Medicine|May 28, 2014
Drug prescription for erectile dysfunction before and after diagnosis of localized prostate cancerAnna Plym, Yasin Folkvaljon, Hans Garmo, et al.
The British Journal of Surgery|February 23, 2024
Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case-control studyGunilla Rask, Charlotta Wadsten, Balazs Acs, et al.
Pageof 27

Showing results (111-120 of 261) with videos related to

Sort By:
Pageof 27
International Journal of Cancer|June 2, 2011
The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS studyMieke Van Hemelrijck, Hans Garmo, Niklas Hammar, et al.
Cancer|April 28, 2011
Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucoseMieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al.
Journal of the National Cancer Institute|August 21, 2010
Effects of prostate-specific antigen testing on familial prostate cancer risk estimatesOla Bratt, Hans Garmo, Jan Adolfsson, et al.
Scandinavian Journal of Urology|April 28, 2020
Adherence to guidelines for androgen deprivation therapy after radical prostatectomy: Swedish population-based studyMagdalena Lycken, Linda Drevin, Hans Garmo, et al.
Plos One|July 23, 2014
Incidence of second malignancies for prostate cancerMieke Van Hemelrijck, Anita Feller, Hans Garmo, et al.
The Journal of Urology|May 13, 2014
Nationwide population based study of infections after transrectal ultrasound guided prostate biopsyKarl-Johan Lundström, Linda Drevin, Stefan Carlsson, et al.
Acta Oncologica (Stockholm, Sweden)|October 31, 2018
Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational studyFrederik Birkebæk Thomsen, Cecilia Bosco, Hans Garmo, et al.
Scandinavian Journal of Urology|November 13, 2023
Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in SwedenRolf Gedeborg, Fredrik Sandin, Camilla Thellenberg-Karlsson, et al.
The Journal of Sexual Medicine|May 28, 2014
Drug prescription for erectile dysfunction before and after diagnosis of localized prostate cancerAnna Plym, Yasin Folkvaljon, Hans Garmo, et al.
The British Journal of Surgery|February 23, 2024
Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case-control studyGunilla Rask, Charlotta Wadsten, Balazs Acs, et al.
Pageof 27